文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部复发前列腺癌再程放疗:前瞻性证据及ReCOG靶区勾画与计划策略综述

Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG).
PubMed 文献 · Clin Transl Radiat Oncol · 2026-07-15

靶区勾画和OAR约束方法异质性大,仅1项正在进行的研究使用累积OAR约束;多数研究报告可接受的泌尿生殖和胃肠道毒性,但部分研究报告较高严重毒性发生率。最佳剂量分割、靶区和OAR约束仍不确定,推荐在前瞻性研究或登记研究中开展治疗。

要点

  • SBRT剂量分割包括25–42.5Gy/5次和36–38Gy/6次,近距离治疗采用LDR和HDR多种方案。
  • 仅1项正在进行的研究使用累积OAR约束,OAR勾画和约束方法异质性大。

核心结论

  • 前列腺癌再程放疗可采用SBRT或近距离治疗,但最佳剂量分割、靶区和OAR约束仍不确定。
  • 推荐在前瞻性研究或登记研究中开展治疗,以生成优化治疗的证据。

研究设计与样本

  • 对已发表和正在进行的前列腺癌SBRT或近距离治疗再程放疗前瞻性研究进行文献综述。

主要发现

  • 靶区勾画采用局部和全腺体±同步整合推量两种方法。
  • SBRT剂量分割范围为25–42.5Gy/5次和36–38Gy/6次,目标优化方法各异。
  • 近距离治疗研究采用低剂量率和高剂量率方法及多种剂量分割方案。
  • OAR勾画和约束方法异质性大,仅1项正在进行的研究使用累积OAR约束。
  • 多数研究报告可接受的泌尿生殖和胃肠道毒性发生率,但部分研究报告较高严重毒性事件发生率。

关键数值与推荐

  • SBRT剂量分割:25–42.5Gy/5次和36–38Gy/6次。
  • 仅1项正在进行的研究使用累积OAR约束。
  • 部分已发表系列随访较短,可能低估晚期毒性发生率。

临床怎么用

  • 前列腺癌再程放疗可采用SBRT或近距离治疗。
  • 治疗应在前瞻性研究或登记研究中进行,需有稳健的靶区定义、治疗实施和全面毒性评估。

局限性

  • 未发现3期临床试验,证据级别有限。
  • 部分已发表系列随访较短,可能低估晚期毒性。
  • 最佳剂量分割、靶区和OAR约束仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is considerable uncertainty regarding the optimum approaches to target volume and organ at risk (OAR) delineation and tolerances to reirradiation for locally recurrent prostate cancer. To address these uncertainties, we undertook a literature review of treatment planning approaches of stereotactic body radiotherapy (SBRT) or brachytherapy reirradiation in published and ongoing prospective studies. Twenty published and 11 ongoing studies were identified. No phase 3 clinical trials were identified. Both focal and whole gland with/without simultaneous integrated boost approaches to target volume delineation were used. SBRT dose-fractionation schedules ranged from 25 to 42.5Gy in 5 fractions and 36-38Gy in 6 fractions with varying approaches to target objectives. Brachytherapy studies utilised both low dose rate and high dose rate approaches and employed a range of dose-fractionation schedules. Approaches to OAR delineation and constraints were heterogenous. No published and only 1 ongoing study utilises cumulative OAR constraints. Acceptable rates of genitourinary and gastrointestinal toxicities were observed in the majority of studies although some studies reported relatively high rates of severe toxicity events. The relatively short follow-up of some published series may underestimate the incidence of late toxicities. There remains uncertainty regarding optimum dose-fractionation schedules, target volumes and OAR constraints and how these influence toxicity. Prostate reirradiation using SBRT or brachytherapy can be used for treatment of locally recurrent prostate cancer. Treatment is recommended within prospective studies or registries with robust target definition, treatment delivery and comprehensive assessment of toxicity so that evidence to optimise treatment can be generated.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Slevin F, Warkentin B, Hansen J, et al. Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG). Clin Transl Radiat Oncol. 2026. PMID: 42540621. doi:10.1016/j.ctro.2026.101229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。